transmembrane p24 trafficking protein 7Genealiases: CGI-109 · Tag · p24g3 · p24gamma3 · p27
Q-omics provides the consensus-scored TMED7 profile across patient tissues and cancer cell-line models. TMED7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMED7 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TMED7 protein abundance shows 30,789 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, LIHC, and LUAD as cancer lineages where TMED7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMED7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMED7 survival associations across molecular data types. TMED7 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMED7 RNA expression–survival associations across cancer types. High TMED7 expression shows unfavorable associations in HNSC, UVM, CESC, LGG and ESCA, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMED7 RNA expression.
This table summarizes TMED7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMED7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMED7 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, KIRC, HNSC and BRCA. The LIHC box plot shows higher TMED7 RNA expression in tumor versus normal tissue (log2 FC = +0.741, t-test p < 0.001).
This table shows molecular features associated with TMED7 in patient tissues and cancer cell lines. In patient samples, TMED7 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMED7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
